|1.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
|2.||Autoimmune Diseases (Autoimmune Disease)
|4.||Demyelinating Diseases (Demyelinating Disease)
|1.||Hartung, Hans-Peter: 111 articles (12/2015 - 12/2002)|
|2.||Kappos, Ludwig: 90 articles (12/2015 - 01/2003)|
|3.||Montalban, Xavier: 83 articles (12/2015 - 02/2002)|
|4.||Gold, Ralf: 80 articles (12/2015 - 03/2002)|
|5.||Giovannoni, Gavin: 78 articles (11/2015 - 10/2002)|
|6.||Comi, Giancarlo: 70 articles (12/2015 - 04/2003)|
|7.||Kieseier, Bernd C: 68 articles (10/2015 - 04/2003)|
|8.||Olsson, Tomas: 67 articles (12/2015 - 03/2002)|
|9.||Steinman, Lawrence: 62 articles (09/2015 - 04/2002)|
|10.||Polman, Chris H: 60 articles (10/2015 - 05/2002)|
|1.||natalizumab (Tysabri)FDA Link
07/01/2011 - "Post hoc analysis of phase III clinical trials and the results of post-approval observational studies indicate that natalizumab significantly increases the proportion of patients with complete clinical and radiological response and is effective in patients with highly active forms of multiple sclerosis and suboptimal response to other treatments. "
09/01/2014 - "Natalizumab (Tysabri(®)) is highly efficacious in controlling disease activity in relapsing multiple sclerosis (MS) patients. "
06/01/2014 - "MRI is the most powerful method in the detection of natalizumab-associated PML by showing imaging patterns helpful in the differentiation between PML and multiple sclerosis lesions. "
01/01/2013 - "Natalizumab inhibits the transmigration of activated T lymphocytes into the brain and is highly efficacious in multiple sclerosis (MS). "
10/29/2012 - "The discovery of natalizumab, a potent therapeutic for multiple sclerosis."
01/01/2010 - "Interferon beta is beneficial in multiple sclerosis; why so remains unclear. "
06/01/2003 - "Although interferon-beta (IFN-beta) has been demonstrated to be effective in the treatment of multiple sclerosis (MS) patients, the mechanism(s) underlying its beneficial effects has not been uncovered yet. "
11/27/1981 - "Ten patients with multiple sclerosis who were treated with human fibroblast interferon (IFN-B) for 6 months showed a significant reduction in their exacerbation rates compared with their rates before treatment (P < .01). "
07/01/2008 - "Several large clinical trials have demonstrated that interferon-beta (IFN-beta) therapy is effective in the treatment of multiple sclerosis (MS) patients. "
12/20/1986 - "In this randomised, double-blind, placebo-controlled, 2-year multicentre study intrathecally administered natural human fibroblast interferon (IFN-B) was effective in reducing exacerbations of multiple sclerosis (MS) in patients with exacerbating/remitting disease. "
|3.||fingolimod (FTY720)FDA Link
12/01/2013 - "The efficacy of the innovative oral drug fingolimod has been proven in the largest study program in multiple sclerosis (MS) demonstrating reduced relapse and reduced disability progression in relapsing-remitting MS patients. "
12/01/2013 - "2-Amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride (FTY720) is a potent immunosuppressant which has been approved by the Food and Drug Administration (FDA) as a new treatment for multiple sclerosis. "
03/15/2013 - "Therefore, FTY720 may be a potent therapeutic agent for not only multiple sclerosis but also other neurologic diseases associated with microglial activation."
05/01/2008 - "A recent Phase II study has demonstrated that oral FTY720 is effective in reducing disease activity in relapsing multiple sclerosis with a favorable adverse-effect profile. "
05/01/2014 - "In the present study, we aimed to investigate whether FTY720, the first approved oral therapy for multiple sclerosis, may be effective in HD models and eventually constitute an alternative therapeutic approach for the treatment of the disease. "
|4.||copolymer 1 (glatiramer acetate)FDA Link
08/01/2000 - "This study demonstrates the sustained efficacy of glatiramer acetate in reducing the relapse rate and in slowing the accumulation of disability in patients with relapsing forms of multiple sclerosis. "
02/01/2009 - "The cumulative evidence for the long-term clinical efficacy of glatiramer acetate is consistent with its dual mechanism of action, reassures the physician that glatiramer acetate can really help improve patient care over the long term, and may contribute to a more positive view of prognosis for patients with multiple sclerosis."
07/01/2013 - "The placebo-controlled phase of the PreCISe study showed that glatiramer acetate delayed onset of clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome and brain lesions on MRI. "
01/01/2010 - "A study included 158 patients stratified into 3 groups: 57 patients with multiple sclerosis (MS) of the main group who were treated with copaxone in dosage 20 mg/d during 4,3±2,6 years, 49 patients without MS with different neurological diseases of the control group and 52 patients diagnosed with "confirmed MS" in the remission stage who were not treated with disease-modifying drugs. "
08/01/2003 - "Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). "
01/01/2001 - "What is the best approach to treating interferon-induced depression in people with multiple sclerosis?"
05/16/2003 - "The mechanism of action of interferons We do not know in the multiple sclerosis but, although exist discrepancies in relation to their degree of effectiveness, fundamentally the dose to use and the administration route, the three available ones have proven to be effective in the reduction of the number of the bouts. "
09/01/2011 - "Human interferon (IFN) β has well established beneficial effects in treating relapsing forms of multiple sclerosis, but current first-line treatment requires frequent (from daily to weekly) parenteral administration. "
11/16/2001 - "In astrocyte culture using serum from patients with an acute episode of multiple sclerosis, but not on treatment with interferon, there was a statistically significant reduction in intercellular communication as compared to astrocytes cultured with serum from these same patients treated with interferon for one year (*p< 0.05; **p< 0.01). "
10/01/2010 - "More than 16 years ago human interferon-β-1b (IFN-β-1β) was shown to be effective in the treatment of the relapsing-remitting form of multiple sclerosis (MS). "
06/01/1995 - "It is important for medical-surgical nurses to understand the pathophysiology of multiple sclerosis, as well as recent evidence suggesting that intravenous methylprednisolone treatment may be effective for treating exacerbations of the disease. "
02/01/1988 - "This study confirms that high dose methylprednisolone is a safe therapeutic option in multiple sclerosis."
06/01/2015 - "High-dose, intravenous methylprednisolone (MP) is the only recommended first-line treatment for multiple sclerosis relapses. "
11/01/2014 - "Short-term, high-dose intravenous methylprednisolone therapy (IVMP), which is called steroid pulse therapy, is widely used as the standard treatment for acute exacerbations of multiple sclerosis (MS), and has been shown to improve neurological symptoms. "
03/01/2002 - "To investigate the efficacy of two different high doses of intravenous methylprednisolone (IVMP) during Multiple Sclerosis (MS) relapses. "
|7.||interferon beta 1aFDA Link
03/01/2006 - "Taken together, these data indicate that patients may benefit from early treatment; the positive results of three double-blind placebo-controlled clinical trials (Early Treatment of Multiple Sclerosis and Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study and BENEFIT) support this conclusion."
06/01/2000 - "Taken together, these data indicate that patients may benefit from early treatment; the positive results of the Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study support this conclusion."
09/28/2000 - "Initiating treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis."
06/01/2012 - "This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers. "
08/01/2006 - "Treatment with interferon beta-1a is well tolerated for a long period of time and may be effective in substandard doses in early onset multiple sclerosis."
06/01/2007 - "Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?"
03/01/2007 - "This study investigated the presence of anti-Hsp90beta antibodies in patients with multiple sclerosis (MS) during remission. "
07/01/2014 - "Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). "
01/01/2014 - "The purpose of this study was to investigate intrathecal production and affinity distributions of Epstein-Barr virus (EBV)-specific antibodies in multiple sclerosis (MS) and controls. "
02/01/2013 - "The objective of this study was to determine the levels of aquaporin-4 (AQP4) antibodies in the cerebrospinal fluid (CSF) of patients meeting the diagnostic criteria for multiple sclerosis (MS) and to describe some of the clinical features of CSF-positive cases. "
|9.||Mitoxantrone (Novantrone)FDA LinkGeneric
12/01/2010 - "Mitoxantrone is highly efficacious in the treatment of severe multiple sclerosis (MS). "
01/01/2004 - "In a double-blind, monotherapy trial (Mitoxantrone In Multiple Sclerosis [MIMS] trial), mitoxantrone 12 mg/m(2) (n = 60) once every 3 months for 2 years significantly improved neurological disability relative to placebo (n = 64), as assessed by changes in mean Kurtzke Expanded Disability Status Scale (EDSS) score, mean Ambulatory Index (AI) score and mean Standardised Neurological Status (SNS) score. "
05/01/2002 - "Recent studies have shown that mitoxantrone is effective in patients with active multiple sclerosis (MS) and that cardiac monitoring is usually required. "
01/01/2007 - "Mitoxantrone has recently been shown to be effective in ameliorating multiple sclerosis activity and reducing the relapse rate. "
11/01/2006 - "Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis."
12/15/2006 - "Many reports have shown that cannabinoids might be beneficial in the symptomatic treatment of multiple sclerosis (MS). "
09/01/2001 - "Data, initially anecdotal, but recently supported on more solid experimental evidence, suggest that cannabinoids might be beneficial in the treatment of some of the symptoms of multiple sclerosis (MS). "
08/01/2004 - "Although cannabinoid treatment of multiple sclerosis symptoms has been shown to be both well tolerated and effective in a number of subjective tests in several small-scale clinical trials, objective measures demonstrating the efficacy of cannabinoids are still lacking. "
05/01/2005 - "The evidence for the therapeutic efficacy of cannabinoids in the treatment of multiple sclerosis (MS) is increasing but is not as yet convincing. "
05/19/2015 - "Clinical trials investigating the analgesic efficacy of cannabinoids in multiple sclerosis have yielded mixed results, possibly due to psychotropic side effects mediated by cannabinoid CB1 receptors. "
04/01/2011 - "Repeated detrusor botulinum neurotoxin type A injections for refractory neurogenic detrusor overactivity in patients with multiple sclerosis have a consistent effect on bladder control, resulting in sustained improvement in quality of life."
11/01/2007 - "Minimally invasive injections of botulinum neurotoxin type A have been shown to be exceptionally effective in producing a prolonged improvement in urinary continence in patients with multiple sclerosis. "
04/01/2011 - "This was a prospective, open label, single center study in 137 patients with multiple sclerosis treated with detrusor injections of botulinum neurotoxin type A with observations made from 2002 to 2009. "
11/01/2015 - "A Comparison of Stated Preferences for Injectable Disease-Modifying Treatments for Multiple Sclerosis: Compliant Vs. Non-Compliant Patients."
11/01/2015 - "Validation of Social Media Analysis for Outcomes Research: Identification of Drivers of Switches between oral and Injectable Therapies for Multiple Sclerosis."
01/01/2010 - "Immunosuppression and immunotherapy have developed as the primary mode of therapy for multiple sclerosis (MS) and are most effective in active, relapsing stages of the disease. "
05/01/1997 - "Thus, it is hoped that this article serves a dual purpose, namely to provide an update on recent advances in immunology, and to serve as a useful source of reference to immunotherapies holding promise for future treatment of multiple sclerosis."
01/01/2015 - "Multiple Sclerosis (MS) is a chronic inflammatory disease of young adults with an increasing number of partially effective immunotherapies and therefore a paradigmatic disease to study patient involvement. "
03/01/2013 - "Our findings have revealed cooperative immunosuppressive interactions between iNKT cells and MDSCs that might be exploited for the development of improved immunotherapies for multiple sclerosis and other autoimmune and inflammatory diseases."
01/01/2014 - "Cyclic double-mutant analog cyclo(139-151) [L(144), R(147)]PLP139-151 has potential for further studies for the immunotherapy of multiple sclerosis."
|3.||Transplantation (Transplant Recipients)
04/01/2010 - "It is therefore reasonable to move mesenchymal stem cells transplantation into properly controlled human studies to explore their potential as a treatment for multiple sclerosis. "
06/15/2005 - "In light of this complex situation, it is concluded that clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature."
10/01/2002 - "[Transplantation of myelinating cells as regenerative therapy for multiple sclerosis - experimental basis and present state of clinical studies]."
12/16/1999 - "The lack of any markers for oligodendrocyte precursors that can be visualized within the intact CNS is a significant barrier to trials of transplantation of these cells which aim to enhance remyelination in multiple sclerosis. "
01/01/1994 - "Developmental studies of oligodendrocyte precursor cell migration and their implications for transplantation as therapy for multiple sclerosis."
11/01/2009 - "Owing to a number of promising results obtained in mouse models of multiple sclerosis, cell therapies implementing hematopoietic, mesenchymal and neural stem cells may provide practical vehicles for in situ immunomodulation, neuroprotection and regeneration. "
04/01/2009 - "The efficacy of many new immunomodulatory therapies for multiple sclerosis (MS) patients has often been disappointing, reflecting our incomplete understanding of this enigmatic disease. "
05/29/2007 - "Based on the efficacy of immunomodulatory therapies in patients with multiple sclerosis (MS), much of the research and thinking about pathogenesis and treatment has traditionally focused on suppressing the immune system. "
04/17/2007 - "MRI has revolutionized the diagnostic accuracy of multiple sclerosis (MS) in adults, and is now used extensively to evaluate efficacy of immunomodulatory therapies. "
04/14/2007 - "[Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple sclerosis]."
|5.||Drug Therapy (Chemotherapy)
01/01/2015 - "It attained very promising results on the datasets we tested it on: in one set of experiments based on a published dataset of response to drug therapy in Multiple Sclerosis patients, ECM used only an average of 40% of a time series and was able to outperform some of the baseline models, which needed the full time series for classification. "
06/01/2009 - "Pharmacotherapy of multiple sclerosis: the PROOF trial."
04/01/2006 - "The objective of this study was to examine the adequacy of antidepressant pharmacotherapy in a sample of patients with multiple sclerosis (MS) treated by neurologists. "
10/01/1997 - "Notwithstanding the absence of long term tolerability data, and data from comparative trials with other agents, interferon-beta-1a represents a promising advance in drug therapy for relapsing multiple sclerosis."
03/01/1996 - "Drug therapy in multiple sclerosis: a study of Nova Scotia senior citizens."